Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Not available.

Saved in:
Bibliographic Details
Main Authors: Pierre Peterlin, Maxime Jullien
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-01-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11927
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832577697788723200
author Pierre Peterlin
Maxime Jullien
author_facet Pierre Peterlin
Maxime Jullien
author_sort Pierre Peterlin
collection DOAJ
description Not available.
format Article
id doaj-art-c1146753b87c43159a4cff95830c4cb6
institution Kabale University
issn 0390-6078
1592-8721
language English
publishDate 2025-01-01
publisher Ferrata Storti Foundation
record_format Article
series Haematologica
spelling doaj-art-c1146753b87c43159a4cff95830c4cb62025-01-30T19:44:19ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-01-01999110.3324/haematol.2025.287378Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des MyélodysplasiesPierre Peterlin0Maxime Jullien1Clinical Hematology, Nantes University Hospital, NantesClinical Hematology, Nantes University Hospital, Nantes Not available. https://haematologica.org/article/view/11927
spellingShingle Pierre Peterlin
Maxime Jullien
Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Haematologica
title Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
title_full Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
title_fullStr Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
title_full_unstemmed Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
title_short Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
title_sort response to comment on flt3 ligand kinetic profile predicts response to treatment in patients with high risk myelodysplastic syndrome chronic myelomonocytic leukemia receiving cpx 351 a study from the groupe francophone des myelodysplasies
url https://haematologica.org/article/view/11927
work_keys_str_mv AT pierrepeterlin responsetocommentonflt3ligandkineticprofilepredictsresponsetotreatmentinpatientswithhighriskmyelodysplasticsyndromechronicmyelomonocyticleukemiareceivingcpx351astudyfromthegroupefrancophonedesmyelodysplasies
AT maximejullien responsetocommentonflt3ligandkineticprofilepredictsresponsetotreatmentinpatientswithhighriskmyelodysplasticsyndromechronicmyelomonocyticleukemiareceivingcpx351astudyfromthegroupefrancophonedesmyelodysplasies